


PTO/SB/08a Substitute for Form 1449A/PTO		Application Number	10/772,964		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	February 4, 2004		
		First Named Inventor	Claudia MATTERN		
		Art Unit	1646		
<i>(Use as many sheets as necessary)</i>		Examiner Name	To Be Assigned		
Sheet	1	of	1	Attorney Docket	8276.85946

Examiner Signature	/Aradhana Sasan/	Date Considered	03/19/2007
-----------------------	------------------	--------------------	------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04.

³Applicant's unique creation designation number (optional). ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. ⁷Applicant is to place a check mark here if English language Translation is attached.

FORM 1449  INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION <small>(use several sheets if necessary)</small>	Docket Number: 08788.0024US01	Application Number: 10/772964
	Applicant: Claudia MATTERN	
	Filing Date: February 4, 2004	Group Art Unit: n/a

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES
/AS/	WO 98/47535	Oct. 1998	WO			
/AS/	GB 2 237 510	May 1991	UK			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
/AS/		Dondeti, Polireddy, et al., "Bioadhesive and formulation parameter affecting nasal absorption", <i>International Journal of Pharmaceutics</i> , 127 (1996) 115-133.				
		Hussain, Anwar A., et al., "Testosterone 17 β -N, N-Dimethylglycinate Hydrochloride: A Prodrug with a Potential for Nasal Delivery of Testosterone", <i>Journal of Pharmaceutical Sciences</i> , Vol. 91, No. 3, March 2002, pp. 785-789.				
		Ko, Kuang-Ta, et al., "Emulsion formulations of testosterone for nasal administration", <i>J. Microencapsulation</i> , 1998, vol. 15, no. 2, pp. 197-205.				
		Cicinelli, Ettore, et al., "Progesterone administration by nasal spray", <i>Fertility and Sterility</i> , vol. 56, no. 1, July 1991, pp. 139-141.				
		Cicinelli, E., et al., "Nasally-administered progesterone: comparison of ointment and spray formulations", Elsevier Scientific Publishers Ireland Ltd., 13 (1991), pp. 313-317.				
		Cicinelli, E., et al., "Progesterone administration by nasal spray in menopausal women: comparison between two different spray formulations", <i>Gynecol. Endocrinol.</i> , 6(1992), pp. 247-251.				
		Cicinelli, Ettore, et al., "Nasal spray administration of unmodified progesterone: evaluation of progesterone serum levels with three different radioimmunoassay techniques", <i>Maturitas Journal of the Climacteric & Postmenopause</i> , 19(1994), pp. 43-52.				
		Steege, John, F., et al., "Bioavailability of nasally administered progesterone", <i>Fertility and Sterility</i> , vol. 46, no. 4, 1986, pp. 727-729.				
▼		Provasi, D., et al., "Nasal delivery progesterone powder formulations comparison with oral administration", <i>Boll. Chim. Farmaceutico</i> , Ann 132, n. 10 (1993), pp. 402-404.				

23552

PATENT TRADEMARK OFFICE

EXAMINER	/Aradhana Sasan/	DATE CONSIDERED	03/19/2007
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.			